缬沙坦预处理对乳鼠心肌细胞缺氧/复氧损伤的保护作用(1)
 |
| 第1页 |
参见附件(3046KB，2页)。
【摘要】目的:探讨缬沙坦预处理对乳鼠心肌细胞缺氧/复氧损伤的保护作用及其机制。方法:常规方法培养心肌细胞，培养72小时后，分为三组：正常对照组、心肌细胞缺氧/复氧损伤组、缬沙坦预处理后心肌细胞缺氧/复氧损伤组。分别观察心肌细胞结构，测定心肌细胞存活率、乳酸脱氢酶(LDH)、丙二醛(MDA)及超氧化物歧化酶(SOD)水平。结果:与对照组比心肌细胞缺氧/复氧损伤组细胞存活率明显下降、培养液中LDH、MDA含量明显增高，SOD含量明显下降；与心肌细胞缺氧/复氧损伤组比，缬沙坦预处理组心肌细胞存活率明显提高，培养液中LDH、MDA含量明显下降、SOD含量明显上升。结论 缬沙坦通过抗氧化、抗脂质过氧化反应，清除氧自由基对乳鼠心肌细胞缺氧/复氧损伤有保护作用。
【关键词】缬沙坦；心肌细胞；缺氧复氧；预处理
【中图分类号】R322.11;R541.4【文献标识码】A【文章编号】1008-6455(2011)08-0582-02
Protective effects of Valsartan pretreatment on hypoxia/reoxygen injury in neonatal SD rat cardiomyocytes
Wang Liang1 Dai Zhenhua2 Chen Peng3
【Abstract】Objective:To observe protective action of Valsartan pretreatment on hypoxia/reoxygen injury in neonatal SD rat cardiomyocytes and to investigate the mechanism.Methods:To establish a model for primary culture of cardiomyocytes injuried by hypoxia/reoxygen. The morphology of cardiomyocytes was observed, and cardiomyocytes fraction surviving were measured, and the activity of lactate dehydrogenase (LDH), malondialdehyde (MDA), superoxide dismutase (SOD) were assayed.Results:Valsartan pretreatment on hypoxia/reoxygen injury in neonatal SD rat cardiomyocytesinhance cardiomyocytes fraction surviving (P<0.05), and decrease the activity of LDH, content of MDA and improve the acivity of SOD in the injuried myocytes (P<0.05). Conclusion:Valsartan pretreatment can prevent the cultured cardiac myocytes during hypoxia/reoxygenation injury obviously. The mechanisms may be as below: Valsartan pretreatment can stabilized the membrane of myocardium, restrict oxygen free radical injury in cardiac myocyte during hypoxia/reoxygenation injury.
【Key words】Valsartan; cultured cardiac myocyte; hypoxia/reoxygenation injury; pretreatment
大量实验显示心肌细胞缺氧/复氧损会引起心肌细胞损伤并引起心肌细胞缺失，在心脏病病理进程中扮演重要的角色[1]。目前已有研究证明，Ang lI受体拮抗剂缬沙坦通过选择性拮抗AT受体，激活AT受体及直接作用，产生抗缺血再灌注损伤心律失常，减少梗死面积，减轻心肌顿抑等多种心肌保护作用[2]。但缬沙坦对体外培养的心肌细胞缺氧/复氧损伤的影响尚未见报道。 我们通过乳鼠心肌细胞原代培养，建立心肌细胞缺氧/复氧损伤的模型，观察缬沙坦对心肌细胞缺氧/复氧损伤的保护作用，在细胞水平探讨它对心肌细胞缺氧/复氧损伤的保护作用和可能的机制。
1 材料与方法
1.1 实验动物 1～2 d龄SD大鼠，雌雄不拘，共260只。
药品及主要试剂。药品：缬沙坦(瑞士原粉，诺华公司惠赠)。试剂：DMEM/F12(1∶1) 培养基(Hyclone公司，美国)， 5-溴脱氧尿嘧啶(5-Brdu ......
您现在查看是摘要介绍页，详见PDF附件(3046KB，2页)。